Westover Capital Advisors LLC Makes New $1.11 Million Investment in Krystal Biotech, Inc. $KRYS

Key Points

• Westover Capital Advisors initiated a $1.11 million position in Krystal Biotech by purchasing 3,332 shares during the third quarter. Institutional investors now own 86.29% of the company.
• Krystal Biotech reported quarterly EPS of $1.79, exceeding analysts’ $1.70 estimate, while revenue of $119.22 million fell slightly short of expectations. Analysts project full-year EPS of $7.33.
• Analysts maintain a favorable view of the stock, with a consensus rating of “Buy” and an average price target of $377.20; KRYS recently opened at $313.66.

Westover Capital Advisors LLC purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,332 shares of the company's stock, valued at approximately $1,108,000.

Other large investors have also bought and sold shares of the company. Silvant Capital Management LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth $30,000. Western Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at about $34,000. USA Financial Formulas bought a new position in shares of Krystal Biotech during the first quarter valued at about $44,000. Integrated Wealth Concepts LLC bought a new position in shares of Krystal Biotech during the second quarter valued at about $46,000. Finally, Signaturefd LLC lifted its position in shares of Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company's stock valued at $56,000 after purchasing an additional 36 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $313.66 on Tuesday. Krystal Biotech, Inc. has a 1 year low of $183.26 and a 1 year high of $382.54. The firm has a market cap of $9.28 billion, a PE ratio of 39.31 and a beta of 0.50. The stock has a fifty day moving average price of $338.84 and a 200-day moving average price of $307.01.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts' consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts' expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on KRYS shares. HC Wainwright reaffirmed a "buy" rating and issued a $361.00 price objective on shares of Krystal Biotech in a research report on Thursday, October 15th. Weiss Ratings upgraded shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday. Chardan Capital raised shares of Krystal Biotech to a "strong-buy" rating in a research report on Monday, August 3rd. Citigroup reissued a "buy" rating on shares of Krystal Biotech in a research report on Thursday, October 15th. Finally, The Goldman Sachs Group began coverage on Krystal Biotech in a research note on Thursday, September 24th. They issued a "buy" rating and a $441.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Krystal Biotech currently has an average rating of "Buy" and a consensus target price of $377.20.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company's stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 13.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.